Sotatercept Beneficial in Recent-Onset Pulmonary Arterial Hypertension?

Pulmonary arterial hypertension (PAH) causes substantial symptoms and often confers a dire prognosis despite advances in medical therapy. Sotatercept, an activin-signaling inhibitor, has emerged as an effective therapy for patients with PAH based on trials in those with long-standing disease. In a new, industry-funded trial, researchers studied the efficacy of sotatercept in patients earlier in the course of their illness.

The study included 320 adults with moderately symptomatic, type 1 PAH diagnosed within the prior year and an intermediate or high risk of death who were receiving either double or triple background therapy. Participants were randomized to receive subcutaneous sotatercept (starting at 0.3 mg/kg, titrated to a target …